CLINICAL AND MORPHOLOGICAL FEATURES AND PROGNOSTIC FACTORS IN BREAST CANCER PATIENTS
Keywords:
breast cancer, clinical and morphological features, prognostic factors, hormonal status, HER2, Ki-67Abstract
Breast cancer remains one of the most common malignant tumors among women and ranks among the leading cancer morbidities. The aim of this study was to evaluate the clinical and morphological features and identify key prognostic factors in breast cancer patients. A retrospective analysis of the medical records of 120 patients treated in oncology departments was conducted. Age and clinical characteristics, histological tumor types, tumor differentiation grade, receptor status (ER, PR, HER2), and the Ki-67 proliferation index were examined. The results showed that hormone receptor-positive tumors have a more favorable prognosis, while HER2-positive and triple-negative tumors are characterized by an aggressive course and poor survival. These findings may contribute to improved risk stratification and individualized therapy for breast cancer patients.
References
1. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71(3): 209–249.
2. Султанова Г.Х., Абдуллаева Д.М. Современные подходы к диагностике и лечению рака молочной железы. Онкология. 2022; 24(2): 45–52.
3. Касымова Н.Н., Каримов Б.Ш. Иммуногистохимические особенности опухолей молочной железы у женщин репродуктивного возраста. Вестник онкологии Узбекистана. 2021; 3(15): 27–31.
4. Hammond M.E., Hayes D.F., Wolff A.C. et al. ASCO/CAP guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2020; 38(12): 1346–1366.
5. Ким С.А., Руденко Е.В. Прогностическое значение Ki-67 при инвазивном раке молочной железы. Российский онкологический журнал. 2021; 26(4): 56–63.
6. Wolff A.C., Hammond M.E., Allison K.H. et al. Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer: ASCO/CAP Guideline Update. Arch Pathol Lab Med. 2018; 142(11): 1364–1382.
7. Давлатова Л.Т., Мирзаева Г.Ю. Эпидемиологические особенности и структура рака молочной железы в Узбекистане. Здравоохранение Узбекистана. 2020; 5(7): 40–45.
8. Perou C.M., Sørlie T., Eisen M.B. et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797): 747–752.
9. Бекмурадова М.К., Ниязова Д.С. Анализ клинико-патологических характеристик и факторов прогноза у пациенток с раком молочной железы. Вестник медицинской науки. 2023; 2(6): 18–25.
10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data. Lancet Oncol. 2018; 19(1): 27–39.
Published
Issue
Section
License
Copyright (c) 2025 Salva Faekovna Dallo (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All Rights Reserved.
